Reactivation of SARS-CoV-2 infection following recovery from COVID-19

被引:11
|
作者
Chen, Zhihai [1 ]
Xie, Wen [2 ]
Ge, Ziruo [1 ,3 ]
Wang, Yajie [4 ]
Zhao, Hong [2 ]
Wang, Jingjing [2 ]
Xu, Yanli [1 ]
Zhang, Wei [1 ]
Song, Meihua [1 ]
Cui, Shuping [1 ,5 ]
Wang, Xiankun [1 ,3 ]
Pan, Calvin Q. [2 ]
机构
[1] Capital Med Univ, Beijing Ditan Hosp, Ctr Infect Dis, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, 8 Jingshun East St, Beijing 100015, Peoples R China
[3] Capital Med Univ, Grad Sch, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Ditan Hosp, Dept Clin Lab, Beijing, Peoples R China
[5] Peking Univ, Ditan Teaching Hosp, Beijing, Peoples R China
关键词
Coronavirus reactivation; COVID-19; relapse; Persistent coronavirus infection; Real-Time reverse; transcription-polymerase chain reaction; Recurrent SARS-CoV-2 infection;
D O I
10.1016/j.jiph.2021.02.002
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Many individuals test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA after recovering from the coronavirus disease (COVID-19), but the incidence of reactivation is unknown. We, therefore, estimated the incidence of reactivation among individuals who had recovered from COVID-19 and determined its predictors. Methods: In this retrospective cohort study, patients with COVID-19 were followed up for at least 14 days after two consecutive negative SARS-CoV-2 polymerase chain reaction test results obtained >= 24 h apart, and the frequency of SARS-CoV-2 reactivation was assessed. Results: Of the 109 patients, 29 (27%) experienced reactivation, and seven (24%) of these were symp-tomatic. The mean period for the real-time PCR tests for SARS-CoV-2 from negative to positive results was 17 days. Compared with patients without reactivation, those with reactivation were significantly younger and more likely to have a lymphocyte count of <1500/mu L (odds ratio [OR]: 0.34, 95% confidence interval [CI]: 0.12-0.94) and two or fewer symptoms (OR: 0.20, 95% CI: 0.07-0.55) during the initial episode. Conclusion: Risk-stratified surveillance should be conducted among patients who have recovered from COVID-19. (c) 2021 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:620 / 627
页数:8
相关论文
共 50 条
  • [31] Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19)
    De Clercq, Erik
    MICROBIOLOGY AUSTRALIA, 2021, 42 (01) : 47 - 53
  • [32] SARS-CoV-2 infection and COVID-19 in asthmatics: a complex relationship
    Chrysanthi Skevaki
    Antonina Karsonova
    Alexander Karaulov
    Daria Fomina
    Min Xie
    Sharon Chinthrajah
    Kari C. Nadeau
    Harald Renz
    Nature Reviews Immunology, 2021, 21 : 202 - 203
  • [33] Dermatomyositis in Association With SARS-CoV-2 Infection or COVID-19 Vaccine
    Diaz-Menindez, Maximiliano
    Sullivan, Megan M.
    Wang, Benjamin
    Majithia, Vikas
    Abril, Andy
    Butendieck Jr, Ronald R.
    Ball, Colleen T.
    Berianu, Florentina
    ARTHRITIS CARE & RESEARCH, 2024, 76 (01) : 98 - 104
  • [34] Important Steps to Control COVID-19/SARS-CoV-2 Infection
    Sudipto Chatterjee
    SN Comprehensive Clinical Medicine, 2020, 2 (4) : 381 - 382
  • [35] SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19
    Yu, Ligen
    Abd Ghani, Mohd Khanapi
    Aghemo, Alessio
    Barh, Debmalya
    Bassetti, Matteo
    Catena, Fausto
    Gallo, Gaetano
    Gholamrezanezhad, Ali
    Kamal, Mohammad Amjad
    Lal, Amos
    Sahu, Kamal Kant
    Saxena, Shailendra K.
    Elmore, Ugo
    Rahimi, Farid
    Robba, Chiara
    Song, Yuanlin
    Xia, Zhengyuan
    Yu, Boxuan
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (39) : 4390 - 4408
  • [36] COVID-19 (SARS-CoV-2) infection presenting as acute urticaria
    Farhan, Mariam
    Bilori, Bilori
    Aronin, Steven
    CLINICS IN DERMATOLOGY, 2021, 39 (02) : 312 - 313
  • [37] Call for Papers: The Pathophysiology of COVID-19 and SARS-CoV-2 Infection
    Morty, Rory E.
    Ziebuhr, John
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2020, 318 (05)
  • [38] SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart
    Dhakal, Bishnu P.
    Sweitzer, Nancy K.
    Indik, Julia H.
    Acharya, Deepak
    William, Preethi
    HEART LUNG AND CIRCULATION, 2020, 29 (07): : 973 - 987
  • [39] Palliative Care in Times of SARS-CoV-2/COVID-19 Infection
    Ariza Galindo, Carlos Jose
    Castiblanco Bautista, Angela Patricia
    UNIVERSITAS MEDICA, 2021, 62 (03):
  • [40] Pharmacological options in treating SARS-CoV-2 infection/COVID-19
    Fabian Akos
    Laszlo Istvan
    Juhasz Marianna
    Berhes Mariann
    Vegh Tamas
    Koszta Gyorgy
    Molnar Csilla
    Fulesdi Bela
    ORVOSI HETILAP, 2020, 161 (17) : 685 - 688